"The cystic fibrosis (CF) drug Orkambi (Vertex Pharmaceuticals) has received a green light from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP).
Orkambi is a fixed-dose oral combination "...
(Generic versions may still be available.)
Care should be exercised in administering Larodopa to patients with a history of myocardial infarction who have residual atrial, nodal or ventricular arrhythmias. If Larodopa is necessary in this type of patient, it should be used in a facility with a coronary care unit or an intensive care unit.
Pyridoxine hydrochloride (vitamin B6) in oral doses of 10 mg to 25 mg rapidly reverses the toxic and therapeutic effects of Larodopa. This should be considered before recommending vitamin preparations containing pyridoxine hydrochloride (vitamin B6).
Patients with chronic wide angle glaucoma may be treated cautiously with Larodopa, provided the intraocular pressure is well controlled and the patient monitored carefully for changes in intraocular pressure during therapy.
Postural hypotensive episodes have been reported as adverse reactions. Therefore, Larodopa should be administered cautiously to patients on antihypertensive drug (for patients receiving pargyline, see note on MAO inhibitors contraindications), and it may be necessary to adjust the dosage of the antihypertensive drugs.
The safety of Larodopa in women who are or who may become pregnant has not been established; hence it should be given only when the potential benefits have been weighed against possible hazards to mother and child. Studies in rodents have shown that levodopa at dosages in excess of 200 mg/kg/day has an adverse effect on fetal and postnatal growth and viability
Larodopa should not be used in nursing mothers.
Safety and effectiveness in pediatric patients have not been established.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 12/8/2004
Additional Dopar Information
- Dopar Drug Interactions Center: levodopa oral
- Dopar Side Effects Center
- Dopar FDA Approved Prescribing Information including Dosage
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.